| ATM | ataxia telangiectasia mutated |
| ATR | ATM- and Rad3-related |
| BACH1 | BRCA1-associated C-terminal helicase 1 |
| BARD1 | BRCA1 Associated RING domain 1 |
| BRIP1 | BRCA1 interacting helicase 1 |
| CAP | College of American Pathologist |
| CHEK2 | checkpoint kinase 2 |
| CHK2 | CHEK2 gene coding checkpoint kinase 2 protein |
| CLIA | Clinical Laboratory Improvement Amendments |
| CtIP | CtBP-interacting protein |
| DSB | double strand break |
| GPV | germline pathogenic variant |
| HBOC | hereditary breast and ovarian cancer syndrome |
| HER2 | human epidermal growth factor |
| HGSC | high-grade serous carcinoma |
| HR | homologous recombination |
| HRD | homologous recombination deficiency |
| MGPT | multi-gene panel testing |
| NGS | next-generation sequencing |
| MMEJ | microhomology-mediated end-joining |
| NHEJ | non-homologous end-joining |
| MRN | MRE11-RAD50-NBS1 (or NBN) |
| NES | nuclear exporting signal |
| PALB2 | partner and localizer of BRCA2 |
| PARP | poly (ADP-ribose) polymerase |
| PARPi | poly (ADP-ribose) polymerase inhibitors |
| RPA | replication protein A |
| RRSO | risk-reducing salpingo-oophorectomy |
| TNBC | triple-negative breast cancer |
| VUS | variant of unknown significance |